NeoGenomics (NEO) Tops Q1 EPS by 2c, reaffirms outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Shipping stocks on fire — but cracks are forming in the rate rally
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
- Turkish Stocks Fall 6%, Triggering Market-wide Circuit Breaker - Bloomberg
Neogenomics (NEO) PT Lowered to $21 at BTIG
May 2, 2024 5:24 AM EDTBTIG analyst Mark Massaro lowered the price target on Neogenomics (NASDAQ: NEO) to $21.00 (from $23.00) while maintaining a Buy rating.
The analyst comments "In this note, we update our NEO model following the company's Q1 call. NEO delivered a good 4% beat on the top line, delivered another quarter of positive Adj. EBITDA, and reiterated... More
